CK Life Sciences Int'l. (Holdings) Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CK Life Sciences Int'l. (Holdings).
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Biotechs winstgroei | 41.8% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Geen updates
Recent updates
CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Oct 04
There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise
May 03CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think
Apr 25CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky
Mar 26Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly
Sep 27Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?
Sep 16Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)
Aug 21These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively
Apr 14CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry
Mar 18If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns
Feb 01
What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?
Jan 04CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet
Dec 09We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide
Nov 18In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat CK Life Sciences Int'l. (Holdings) onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2024 | 5,379 | -19 | 418 | 579 | N/A |
| 3/31/2024 | 5,351 | -1 | 385 | 547 | N/A |
| 12/31/2023 | 5,323 | 17 | 353 | 514 | N/A |
| 9/30/2023 | 5,318 | 61 | 191 | 372 | N/A |
| 6/30/2023 | 5,314 | 104 | 100 | 230 | N/A |
| 3/31/2023 | 5,295 | 118 | 137 | 297 | N/A |
| 12/31/2022 | 5,276 | 132 | 175 | 364 | N/A |
| 9/30/2022 | 5,290 | 130 | 302 | 486 | N/A |
| 6/30/2022 | 5,305 | 128 | 430 | 608 | N/A |
| 3/31/2022 | 5,353 | 145 | 318 | 516 | N/A |
| 12/31/2021 | 5,402 | 163 | 206 | 424 | N/A |
| 9/30/2021 | 5,302 | 150 | 107 | 429 | N/A |
| 6/30/2021 | 5,201 | 138 | 7 | 435 | N/A |
| 3/31/2021 | 5,072 | 132 | 79 | 483 | N/A |
| 12/31/2020 | 4,943 | 125 | 151 | 531 | N/A |
| 9/30/2020 | 4,846 | 112 | 139 | 433 | N/A |
| 6/30/2020 | 4,750 | 98 | 128 | 335 | N/A |
| 3/31/2020 | 4,859 | 140 | 155 | 357 | N/A |
| 12/31/2019 | 4,967 | 182 | 181 | 379 | N/A |
| 9/30/2019 | 5,128 | 223 | 90 | 337 | N/A |
| 6/30/2019 | 5,288 | 263 | -1 | 295 | N/A |
| 3/31/2019 | 5,261 | 263 | -29 | 263 | N/A |
| 12/31/2018 | 5,233 | 263 | -57 | 231 | N/A |
| 9/30/2018 | 5,077 | 261 | N/A | N/A | N/A |
| 6/30/2018 | 4,920 | 259 | 165 | 237 | N/A |
| 3/31/2018 | 4,807 | 259 | N/A | 186 | N/A |
| 12/31/2017 | 4,693 | 258 | N/A | 135 | N/A |
| 9/30/2017 | 4,674 | 247 | N/A | N/A | N/A |
| 6/30/2017 | 4,655 | 236 | N/A | 352 | N/A |
| 3/31/2017 | 4,762 | 244 | N/A | 396 | N/A |
| 12/31/2016 | 4,869 | 253 | N/A | 439 | N/A |
| 9/30/2016 | 4,933 | 240 | N/A | N/A | N/A |
| 6/30/2016 | 4,998 | 228 | N/A | 314 | N/A |
| 3/31/2016 | 4,959 | 223 | N/A | 309 | N/A |
| 12/31/2015 | 4,919 | 219 | N/A | 304 | N/A |
| 9/30/2015 | 4,953 | 257 | N/A | N/A | N/A |
| 6/30/2015 | 4,987 | 296 | N/A | 263 | N/A |
| 3/31/2015 | 4,970 | 280 | N/A | 294 | N/A |
| 12/31/2014 | 4,954 | 264 | N/A | 325 | N/A |
| 9/30/2014 | 4,930 | 250 | N/A | 312 | N/A |
| 6/30/2014 | 4,907 | 236 | N/A | 300 | N/A |
| 3/31/2014 | 4,939 | 232 | N/A | 283 | N/A |
| 12/31/2013 | 4,971 | 229 | N/A | 267 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if 775's forecast earnings growth is above the savings rate (2.3%).
Winst versus markt: Insufficient data to determine if 775's earnings are forecast to grow faster than the Hong Kong market
Hoge groeiwinsten: Insufficient data to determine if 775's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if 775's revenue is forecast to grow faster than the Hong Kong market.
Hoge groei-inkomsten: Insufficient data to determine if 775's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 775's Return on Equity is forecast to be high in 3 years time